Related Experiment Video
Updated: May 30, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Glycemic control: how tight in the intensive care unit?
Aaron J Weiss1, Jeffrey I Mechanick
1Department of Cardiothoracic Surgery, Mount SinaiSchool of Medicine, New York, New York, USA.
Seminars in Thoracic and Cardiovascular Surgery
|August 3, 2011
Summary
Optimizing blood glucose control in critical illness is complex. For cardiac surgery patients in the ICU, a target of 80-110 mg/dL is feasible with intensive insulin therapy and safety protocols.
Area of Science:
- Critical care medicine
- Endocrinology
- Cardiovascular surgery
Background:
- Glycemic control in critical illness remains debated since the 2001 Leuven study.
- Conflicting evidence and practice variations challenge optimal blood glucose targets.
- Patient safety concerns have shifted targets towards more liberal ranges (140-180 mg/dL).
Purpose of the Study:
- To present a population-specific glycemic control strategy for cardiac surgery patients in the ICU.
- To reconcile evidence with real-world variables for optimal blood glucose management.
- To propose a stepwise approach for adjusting glycemic targets.
Main Methods:
- Position paper based on a detailed examination of extant evidence.
- Analysis of factors influencing clinical practice patterns in intensive care units.
- Consideration of real-life variables including safety protocols and staff training.
Main Results:
- A strict glycemic target (80-110 mg/dL) is achievable in cardiac surgery ICUs under specific conditions.
- Conditions include intensive insulin therapy, nutrition support, low hypoglycemia rates, safety mechanisms, trained staff, and administrative support.
- A stepwise approach for target adjustment is recommended for ICUs not meeting these criteria.
Conclusions:
- Cardiac surgery ICUs with robust protocols can maintain strict glycemic targets (80-110 mg/dL).
- A gradual transition from liberal to stricter targets is advised for other ICUs.
- Performance-based evaluation is key to successful glycemic control strategy implementation.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
